Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study

OBJECTIVE: Assess cancer risks with Janus kinase inhibitors (JAKi) versus biological disease-modifying antirheumatic drugs (bDMARDs) in clinical practice. METHODS: Cohort study of patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) initiating treatment with JAKi, tumour necrosis fac...

Descripción completa

Detalles Bibliográficos
Autores principales: Huss, Viking, Bower, Hannah, Hellgren, Karin, Frisell, Thomas, Askling, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Inflammatory Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314043/
https://www.ncbi.nlm.nih.gov/pubmed/36868796
http://dx.doi.org/10.1136/ard-2022-223636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314043/
https://www.ncbi.nlm.nih.gov/pubmed/36868796
http://dx.doi.org/10.1136/ard-2022-223636

Ejemplares similares